https://pharmoniq.com/news/molecular-partners-cuts-up-to-44-percent-of-staff-radiotherapy-pivot PharmoniQ en 2026-10-29T14:10:30.567Z Molecular Partners to Cut Up to 44% of Staff in Radiotherapy Pivot Molecular Partners, layoffs, radiopharmaceuticals, Orano Med, small cell lung cancer https://pharmoniq.com/news/zymeworks-roche-zw209-dll3-licence-deal-55-million-upfront PharmoniQ en 2026-10-29T08:30:47.664Z Zymeworks to Get $55M Upfront, Up to $813M, in Roche Licence Deal Zymeworks, Roche, licensing deal, small cell lung cancer, T cell engager https://pharmoniq.com/news/lilly-retatrutide-tops-ozempic-type-2-diabetes-phase-3-trial PharmoniQ en 2026-10-28T14:01:23.951Z Lilly's Retatrutide Cuts Body Weight Up to 20.9%, Beating Ozempic Eli Lilly, retatrutide, Novo Nordisk, type 2 diabetes, clinical trials https://pharmoniq.com/news/artiva-cuts-94-percent-staff-ends-allonk-after-two-deaths PharmoniQ en 2026-10-28T08:08:23.290Z Artiva Cuts 94% of Staff as Trial Deaths, Weak Data End AlloNK Artiva Biotherapeutics, layoffs, cell therapy, autoimmune disease, San Diego